 After GSK’s Lymerix, the only Lyme disease vaccine ever approved, was pulled from the market in 2002 amid a safety controversy, the field went dark and then stalled for more than two decades. Now, Pfizer and Valneva are advancing a new candidate to prevent the tick-borne illness. But will mixed trial data lead to a win or set the market back once again? 
Content mobilized by FeedBlitz RSS Services, the premium FeedBurner alternative. | 
